Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
40 hedge funds and large institutions have $13.5M invested in Carisma Therapeutics in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 4 closing their positions.
1,120% more call options, than puts
Call options by funds: $183K | Put options by funds: $15K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
43% more capital invested
Capital invested by funds: $9.47M → $13.5M (+$4.05M)
11% more funds holding
Funds holding: 36 → 40 (+4)
0.08% more ownership
Funds ownership: 0.77% → 0.85% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$721K |
| 2 |
EP
Eversept Partners
New York
|
+$472K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$342K |
| 4 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$136K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$449K |
| 2 |
BlackRock
New York
|
-$167K |
| 3 |
Bank of New York Mellon
New York
|
-$27.4K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$17.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$12.4K |
CARM Hedge Fund Activity: Q2 2020 in Review
40 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2020, worth a combined $13.5M — up 43% from $9.47M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CARM positions and 4 closed out — a net gain of 4 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $721K. The largest seller was Susquehanna International Group, cutting an estimated $449K.
- 40 institutional investors held Carisma Therapeutics (CARM) as of Q2 2020, up from 36 in Q1 2020.
- Funds reported $13.5M of Carisma Therapeutics stock for Q2 2020, up 43% quarter-over-quarter.
- 8 funds opened new Carisma Therapeutics positions in Q2 2020 and 4 closed out, a net change of +4 holders.
- The largest Carisma Therapeutics buyer in Q2 2020 was Renaissance Technologies, an estimated $721K added.
- The largest Carisma Therapeutics seller in Q2 2020 was Susquehanna International Group, an estimated $449K sold.
Based on aggregated 13F filings for Q2 2020.